Atlas Trials

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Clinical trial NCT03208218 · COMPLETED

Trial details

NCT number
NCT03208218
Sponsor
Samyang Biopharmaceuticals Corporation
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy, Male
Start date
2016-08-17
Primary completion
2016-08-25
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.